Prescient Therapeutics Limited (PTX.AX)
ASX · AUD · Healthcare · Biotechnology
A$0.054 (+5.88%) as of
Key statistics
- Market cap
- 61.77M
- Forward P/E
- 5.40
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.0450 – 0.1250
- Beta
- 0.85
- Revenue (TTM)
- 3.45M
- Profit margin
- -202.91%
- Volume
- 271.97k
About Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company is also developing cell therapy platforms, including CellPryme, a high-performance cell therapy enhancement platform; and OmniCAR, is a platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Melbourne, VIC, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.